Literature DB >> 15189455

Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities.

Catherine Goodman1, S Patrick Kachur, Salim Abdulla, Eleuther Mwageni, Joyce Nyoni, Joanna A Schellenberg, Anne Mills, Peter Bloland.   

Abstract

OBJECTIVES: To characterize availability of fever and malaria medicines within the retail sector in rural Tanzania, assess the likely public health implications, and identify opportunities for policy interventions to increase the coverage of effective treatment.
METHODS: A census of retailers selling drugs was undertaken in the areas under demographic surveillance in four Tanzanian districts, using a structured questionnaire.
RESULTS: Drugs were stocked by two types of retailer: a large number of general retailers (n = 675) and a relatively small number of drug shops (n = 43). Almost all outlets stocked antipyretics/painkillers. One-third of general retailers stocking drugs had antimalarials, usually chloroquine alone. Almost all drug shops stocked antimalarials (98%): nearly all had chloroquine, 42% stocked quinine, 37% sulphadoxine-pyrimethamine and 30% amodiaquine. A large number of antimalarial brands were available. Population ratios indicate the relative accessibility of retail drug providers compared with health facilities. Drug shop staff generally travelled long distances to buy from drugs wholesalers or pharmacies. General retailers bought mainly from local general wholesalers, with a few general wholesalers accounting for a high proportion of all sources cited.
CONCLUSIONS: Drugs were widely available from a large number of retail outlets. Potential negative implications include provision of ineffective drugs, confusion over brand names, uncontrolled use of antimalarials, and the availability of components of potential combination therapy regimens as monotherapies. On the other hand, this active and highly accessible retail market provides opportunities for improving the coverage of effective antimalarial treatment. Interventions targeted at all drug retailers are likely to be costly to deliver and difficult to sustain, but two promising points for targeted intervention are drug shops and selected general wholesalers. Retail quality may also be improved through consumer education, and modification of the chemical quality, packaging and price of products entering the retail distribution chain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189455     DOI: 10.1111/j.1365-3156.2004.01245.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  44 in total

1.  The fallacy of competing interest statements: no shortcut to rigour in research.

Authors:  Kara G Hanson; Lucy Gilson; Catherine Goodman; Anne Mills
Journal:  J R Soc Med       Date:  2009-04       Impact factor: 5.344

Review 2.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

3.  A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops.

Authors:  Justin M Cohen; Oliver Sabot; Kate Sabot; Megumi Gordon; Isaac Gross; David Bishop; Moses Odhiambo; Yahya Ipuge; Lorrayne Ward; Alex Mwita; Catherine Goodman
Journal:  BMC Health Serv Res       Date:  2010-07-02       Impact factor: 2.655

Review 4.  Retail sector distribution chains for malaria treatment in the developing world: a review of the literature.

Authors:  Edith Patouillard; Kara G Hanson; Catherine A Goodman
Journal:  Malar J       Date:  2010-02-11       Impact factor: 2.979

5.  Factors influencing implementation of the Ministry of Health-led private medicine retailer programmes on malaria in Kenya.

Authors:  Yvonne Rowa; Timothy O Abuya; Wilfred K Mutemi; Sam Ochola; Sassy Molyneux; Vicki Marsh
Journal:  BMC Public Health       Date:  2010-02-24       Impact factor: 3.295

6.  Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.

Authors:  Allen L Malisa; Richard J Pearce; Salim Abdulla; Hassan Mshinda; Patrick S Kachur; Peter Bloland; Cally Roper
Journal:  Malar J       Date:  2010-07-05       Impact factor: 2.979

7.  The quest for universal access to effective malaria treatment: how can the AMFm contribute?

Authors:  Lloyd Matowe; Olusoji Adeyi
Journal:  Malar J       Date:  2010-10-08       Impact factor: 2.979

Review 8.  Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved?

Authors:  Catherine Goodman; William Brieger; Alasdair Unwin; Anne Mills; Sylvia Meek; George Greer
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

9.  Drug shop regulation and malaria treatment in Tanzania--why do shops break the rules, and does it matter?

Authors:  Catherine Goodman; S Patrick Kachur; Salim Abdulla; Peter Bloland; Anne Mills
Journal:  Health Policy Plan       Date:  2007-10-04       Impact factor: 3.344

10.  Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania.

Authors:  Oliver J Sabot; Alex Mwita; Justin M Cohen; Yahya Ipuge; Megumi Gordon; David Bishop; Moses Odhiambo; Lorrayne Ward; Catherine Goodman
Journal:  PLoS One       Date:  2009-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.